Clinical Trials: Clinical Scientists

Clinical Scientists involved in the
Cancer Immunology Program

Affiliations & Collaborations

The clinical program at the GSCC is currently run out of the Nuclear Medicine Facility at the Belleville facility. However, a major thrust of our clinical program involves an Outreach Program that is intended to bring community physicians closer to clinical research. We have had tremendous interest by several community hospitals and physicians in this type of program that will make GSCC trials available to local medical centers. Investigators at the Center work closely with the oncologists at each institution to develop protocols of mutual interest that introduces biologicals into the treatment of their cancer patients. Thus, the Center works in cooperation, not in competition, with the local hospitals to provide new technologies that would not ordinarily be available to the cancer patient. Such an arrangement allows the patient and his/her private physician to maintain their trusted relationship while receiving new forms of treatment or diagnostic procedures.

Arnold I Brenner, D.O., M.M.M., C.P.E.: Dr. Brenner is a Nuclear Medicine physician at the Garden State Cancer Center. He received his D.O. from the University of Osteopathic Medicine and Surgery, Des Moines, IA in 1975, and his M.M.M. from the Heinz School of Public Policy and Management at Carnegie Mellon University, Pittsburgh, PA in 2000. Dr. Brenner's main areas of interest include radioimmunotherapy and development of improved analytic correlations between dosimetry measurement and actual toxicity. He is a Clinical Assistant Professor of Pediatrics and Medicine at the University of Medicine and Dentistry of New Jersey, Newark, NJ and a Visiting Assistant Professor of Nuclear Medicine at the Albert Einstein College of Medicine, Bronx, NY. Dr. Brenner is certified by the American Board of Nuclear Medicine, the American Board of Quality Assurance and Utilization Review Physicians, and the Certifying Commission in Medical Management. He has experience in medical staff leadership and in medical management in a number of New Jersey healthcare organizations including the St. Barnabas Healthcare System, United Hospital Medical Center and Cathedral Healthcare System. . Dr. Brenner has been voted by peers as one of the "Best Doctors in America" and as one of the "Top Doctors in New Jersey" (New Jersey Monthly).

David M. Goldenberg, Sc.D., M.D.: Dr. Goldenberg has pioneered the technology of radiolabeled antibodies for detection, localization and therapy of cancer since the 1970's and remains one of the most prominent leaders of this field. His leadership has been responsible for the development of several panels of antibodies against a wide variety of tumors, specialized radiolabeling technologies, engineered antibodies, and continuing development of new approaches to utilize these technologies. Over his career in this field, Dr. Goldenberg's clinical immunology research program has enrolled over 1800 patients, performing more than 3500 injections of radiolabeled antibodies for diagnostic or therapeutic purposes.

Jack Burton, M.D.: Dr. Burton is the Associate Director of Clinical Oncology. He is the Principal Investigator for clinical protocols on Non-Hodgkin's Lymphoma and Ovarian Cancer. Dr. Burton is also taking an active role in the Outreach Program, meeting with local oncologists and discussing ways to integrate GSCC's clinical programs with other institutions. Dr. Burton maintains a laboratory program that is involved in the investigation of how to best integrate cytokines and antibody-based approaches to the treatment of cancer. Additional studies are being conducted on the anti-cancer effects of novel drugs when used alone or in combination with standard cancer treatment modalities.

Robert M. Sharkey, Ph.D.: Dr. Sharkey is currently the Director of Clinical Research Administration. Dr. Sharkey is principally responsible for the oversight of clinical trials and development of new trials based upon the Center's laboratory research efforts. As Director of Clinical Research Administration, Dr. Sharkey is responsible for developing the regulatory submissions and oversight of the monitoring program for all of the clinical investigations to ensure compliance with Good Clinical Practices. In addition, he supervises the support laboratories for the clinical trials, such as the antibody production and radiolabeling facilities. Dr. Sharkey also continues to be involved in the evaluation of antibody targeting in preclinical models, focusing on the use of pretargeting technologies.